Dec 01, 2020 / 01:50PM GMT
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - MD
Okay. Thanks, everyone, for joining us this morning. I'm Vijay Kumar. I cover life sciences and med tech at Evercore. A real pleasure to have with us Danaher. Representing the company, we have the CEO, Rainer Blair. We have the CFO, Matt McGrew. And plus from IR, we have Matt Gugino. Gentlemen, thanks for taking the time this morning. And Rainer, excited to have you on your first public, I guess, conference call with investors perhaps in a more formal setting, if you will.
Questions and Answers:
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - MDMaybe we'll start with some topical questions, Rainer, if you don't mind. Second wave has been a topical question for people. How should we think about this rising second wave and perhaps impact on the business? It looks like the 3Q step-up -- sequential step-up in 3Q versus 2Q was pretty remarkable. It came in above expectations. But perhaps, should we be a little bit more cautious into Q4? How